

免疫異常疾患研究室 2006(平成18)年度業績 (欧文文献)

(太字アンダーラインは当院所属)

1. Kudo-Tanak E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, Harada Y, Katada Y, Ikeue H, Umeshita-Sasai M, Miyatake K, Saeki Y.
Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis (RA) in early undifferentiated arthritis.
Clin Rheumatol 26(10):1627-33, 2007
2. Ishii M, Muramoto Y, Kosaka H, Ohshima S, Mima T, Katada Y, Hirohata S, Saeki Y.
A serological switching from anti-dsDNA to anti-Sm antibodies coincided with severe clinical manifestations of systemic lupus erythematosus.
(hemophagocytosis, profundus and psychosis)
Lupus 16(1):67-69, 2007
3. Katada Y, Harada Y, Azuma N, Matsumoto K, Terada H, Kudo E, Ishii M, Yamane H, Yamamoto S, Ohshima S, Mima T, Tanaka T, Saeki Y.
Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.
Mod Rheumatol 16(4):256-9, 2006
4. Ishii M, Iwai K, Koike M, Ohshima S, Kudo-Tanaka E, Ishii T, Mima T, Katada Y, Miyatake K, Uchiyama Y, Saeki Y.
RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis.
J Bone Miner Res 21(6):965-76, 2006
5. Ishii M, Kurachi Y.
Muscarinic acetylcholine receptor, G protein, phospholipase C, adenylyl cyclase, G protein-gated potassium channel, pharmacology, gene targeting.
Current Pharmaceutical Design 3573-3581, 2006